Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prescription Drug Spending Remains Low, As Generics Continue To Dominate -Medco

This article was originally published in The Pink Sheet Daily

Executive Summary

OTC entries drive Rx utilization down.

You may also be interested in...

Oncology Drug Spending By Health Plans May Rise 50% By 2010 – Medco

Long-term cancer treatment with targeted oral therapies will spur a 46 percent to 53 percent surge in health plan spending on oncology drugs within the next three years, Medco predicts in its 2008 Drug Trend Report (see chart: "1Drug Spending By Health Plans: 2008-2010 Forecast")

Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales

Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.

Affymax's Share Price Stumbles On Questionable Phase III Hematide Data

Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts